Levemir医薬品の考察と市場予測 - 2032年

当レポートでは、主要7市場（米国、ドイツ、フランス、イタリア、スペイン、英国、日本）におけるLevemirについて調査分析し、作用機序、用法と用量、研究開発活動に関する考察や、市場予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 1型糖尿病におけるLevemirの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品のプロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 Levemir市場の評価

• 1型糖尿病におけるLevemirの市場見通し
• 主要7市場の分析
  • 主要7市場の1型糖尿病向けLevemirの市場規模
• 市場の分析：国別
  • 米国の1型糖尿病向けLevemirの市場規模
  • ドイツの1型糖尿病向けLevemirの市場規模
  • 英国の1型糖尿病向けLevemirの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: LEVEMIR, Clinical Trial Description, 2023
• Table 2: LEVEMIR, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: LEVEMIR Market Size in the 7MM, in USD million (2019-2032)
• Table 6: LEVEMIR Market Size in the US, in USD million (2019-2032)
• Table 7: LEVEMIR Market Size in Germany, in USD million (2019-2032)
• Table 8: LEVEMIR Market Size in France, in USD million (2019-2032)
• Table 9: LEVEMIR Market Size in Italy, in USD million (2019-2032)
• Table 10: LEVEMIR Market Size in Spain, in USD million (2019-2032)
• Table 11: LEVEMIR Market Size in the UK, in USD million (2019-2032)
• Table 12: LEVEMIR Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: LEVEMIR Market Size in the 7MM, USD million (2019-2032)
• Figure 2: LEVEMIR Market Size in the United States, USD million (2019-2032)
• Figure 3: LEVEMIR Market Size in Germany, USD million (2019-2032)
• Figure 4: LEVEMIR Market Size in France, USD million (2019-2032)
• Figure 5: LEVEMIR Market Size in Italy, USD million (2019-2032)
• Figure 6: LEVEMIR Market Size in Spain, USD million (2019-2032)
• Figure 7: LEVEMIR Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: LEVEMIR Market Size in Japan, USD million (2019-2032)

“"LEVEMIR Drug Insight and Market Forecast - 2032" report provides comprehensive insights about LEVEMIR for type 1 diabetes mellitus in the seven major markets. A detailed picture of the LEVEMIR for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the LEVEMIR for type 1 diabetes mellitus. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LEVEMIR market forecast analysis for type 1 diabetes mellitus in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in type 1 diabetes mellitus.

Drug Summary:

LEVEMIR is a soluble, basal insulin analogue with a prolonged duration of effect. Insulin detemir (rys) is produced by recombinant DNA technology using Saccharomyces cerevisiae. LEVEMIR is a clear, colourless, neutral solution of insulin detemir 100 U/mL. It is a solution for injection. One unit of insulin detemir contains 0.142 mg salt-free anhydrous insulin detemir. One unit (U) of insulin detemir corresponds nominally to one IU of human insulin. LEVEMIR is presented in 3 mL Penfill cartridges made of glass, closed with a rubber disc. The Penfill cartridges are designed to be used with Novo Nordisk insulin delivery systems and are also included in the FLEXPEN pre-filled syringes. It is for subcutaneous administration only by injection in the thigh, abdominal wall, the upper arm, or the gluteal region.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the LEVEMIR description, mechanism of action, dosage and administration, research and development activities in type 1 diabetes mellitus.
• Elaborated details on LEVEMIR regulatory milestones and other development activities have been provided in this report.
• The report also highlights the LEVEMIR research and development activities in type 1 diabetes mellitus across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around LEVEMIR.
• The report contains forecasted sales of LEVEMIR for type 1 diabetes mellitus till 2032.
• Comprehensive coverage of the late-stage emerging therapies for type 1 diabetes mellitus.
• The report also features the SWOT analysis with analyst views for LEVEMIR in type 1 diabetes mellitus.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LEVEMIR Analytical Perspective by DelveInsight

In-depth LEVEMIR Market Assessment

This report provides a detailed market assessment of LEVEMIR for type 1 diabetes mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

LEVEMIR Clinical Assessment

The report provides the clinical trials information of LEVEMIR for type 1 diabetes mellitus covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for type 1 diabetes mellitus is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LEVEMIR dominance.
• Other emerging products for type 1 diabetes mellitus are expected to give tough market competition to LEVEMIR and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LEVEMIR in type 1 diabetes mellitus.
• Our in-depth analysis of the forecasted sales data of LEVEMIR from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LEVEMIR in type 1 diabetes mellitus.

Key Questions:

• What is the product type, route of administration and mechanism of action of LEVEMIR?
• What is the clinical trial status of the study related to LEVEMIR in type 1 diabetes mellitus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LEVEMIR development?
• What are the key designations that have been granted to LEVEMIR for type 1 diabetes mellitus?
• What is the forecasted market scenario of LEVEMIR for type 1 diabetes mellitus?
• What are the forecasted sales of LEVEMIR in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to LEVEMIR for type 1 diabetes mellitus?
• Which are the late-stage emerging therapies under development for the treatment of type 1 diabetes mellitus?

Table of Contents

1. Report Introduction

2. LEVEMIR Overview in type 1 diabetes mellitus

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. LEVEMIR Market Assessment

• 5.1. Market Outlook of LEVEMIR in type 1 diabetes mellitus
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of LEVEMIR in the 7MM for type 1 diabetes mellitus
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of LEVEMIR in the United States for type 1 diabetes mellitus
  • 5.3.2. Market Size of LEVEMIR in Germany for type 1 diabetes mellitus
  • 5.3.3. Market Size of LEVEMIR in France for type 1 diabetes mellitus
  • 5.3.4. Market Size of LEVEMIR in Italy for type 1 diabetes mellitus
  • 5.3.5. Market Size of LEVEMIR in Spain for type 1 diabetes mellitus
  • 5.3.6. Market Size of LEVEMIR in the United Kingdom for type 1 diabetes mellitus
  • 5.3.7. Market Size of LEVEMIR in Japan for type 1 diabetes mellitus

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options